BALCAO · PHARMACEUTICAL PREPARATIONS
Regen Biopharma, Inc. RGBP
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$236,561
▲ 0.0% vs FY2024
EPS · FY25
$-0.05
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-538.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 236,561.00
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 539 cents on every revenue dollar this year.
Per share
USD -0.05
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-143.1%
Net margin-538.8%
Return on assets-585.0%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+16.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+23.5%
+16.5%
+2.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 274,628.00
total assets, end of FY2025
Total assetsUSD 274,628.00
EquityUSD -6.3M
CashUSD 69,555.00
Current ratio0.04×
Equity funds -2287% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.05
−0.16
0.29
0.71
−0.00
0.00
−0.00
−0.03
−0.04
−0.06
−0.13
−0.01
−0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
−306.3
Shares out B
0.04
0.01
0.00
0.00
4.35
1.61
0.18
0.18
0.14
0.14
0.11
0.05
0.05
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed